Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Chilton Capital Management LLC Boosts Holdings in Johnson & Johnson $JNJ
04:54am, Thursday, 29'th Jan 2026
Chilton Capital Management LLC increased its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 44.0% during the third quarter, according to its most recent disclosure with the Securities and Ex
4,192 Shares in Johnson & Johnson $JNJ Acquired by Clarendon Private LLC
04:54am, Thursday, 29'th Jan 2026
Clarendon Private LLC bought a new stake in shares of Johnson and Johnson (NYSE: JNJ) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Excha
Fortis Capital Advisors LLC Has $1.04 Million Stake in Johnson & Johnson $JNJ
04:10am, Thursday, 29'th Jan 2026
Fortis Capital Advisors LLC lifted its position in shares of Johnson and Johnson (NYSE: JNJ) by 170.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Ex
Belpointe Asset Management LLC Purchases 4,566 Shares of Johnson & Johnson $JNJ
04:10am, Thursday, 29'th Jan 2026
Belpointe Asset Management LLC grew its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 30.0% during the third quarter, according to the company in its most recent filing with the Securities
Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25%
03:01pm, Wednesday, 28'th Jan 2026
Exploring Strategic Moves in the Health Sciences Sector Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for
Dividend Growers: 2 Stocks That Could Be Worth $1 Trillion in 7 Years
01:05pm, Wednesday, 28'th Jan 2026
Visa's terrific business should help support its dividend program. Johnson & Johnson has over 50 years of consecutive dividend growth.
Should You Stay Invested in J&J Stock After Q4 Beat & Solid Guidance?
12:10pm, Wednesday, 28'th Jan 2026
JNJ beat Q4 expectations and guided 2026 sales to be in the range of $100-$101B, with Innovative Medicine and MedTech growth offsetting Stelara LOE.
Johnson & Johnson: Strong Momentum Heading Into 2026
09:38am, Wednesday, 28'th Jan 2026
Johnson & Johnson remains a buy as business momentum accelerates, with Q4 revenue up 9.1% YoY and strong U.S. sales resilience. Their deal with the Trump Administration eliminates tariffs in exchange
Cooke & Bieler LP Has $121.24 Million Stock Holdings in Johnson & Johnson $JNJ
06:49am, Wednesday, 28'th Jan 2026
Cooke and Bieler LP cut its holdings in Johnson and Johnson (NYSE: JNJ) by 12.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund
Johnson & Johnson $JNJ Shares Purchased by Exchange Bank
06:49am, Wednesday, 28'th Jan 2026
Exchange Bank lifted its holdings in Johnson and Johnson (NYSE: JNJ) by 18.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange
Investors Buy Large Volume of Call Options on Johnson & Johnson (NYSE:JNJ)
06:14am, Wednesday, 28'th Jan 2026
Johnson and Johnson (NYSE: JNJ - Get Free Report) saw unusually large options trading on Tuesday. Stock traders acquired 37,990 call options on the company. This is an increase of approximately 23% co
3 Dividend Stocks to Hold for the Next 20 Years
06:05am, Wednesday, 28'th Jan 2026
Chevron operates in all three phases of the oil value chain. Procter & Gamble has increased its annual dividend for 69 consecutive years.
AEGON ASSET MANAGEMENT UK Plc Grows Position in Johnson & Johnson $JNJ
03:32am, Wednesday, 28'th Jan 2026
AEGON ASSET MANAGEMENT UK Plc lifted its position in shares of Johnson and Johnson (NYSE: JNJ) by 11.3% during the undefined quarter, according to its most recent disclosure with the Securities and Ex
Quadruplet regimen demonstrated significantly deeper and more durable responses, higher MRD negativity and improved progression-free survival versus a standard of care Approval marks the twe
J&J Targets $100B+ Sales in 2026 as Growth Accelerates in Both Units
11:55am, Tuesday, 27'th Jan 2026
On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, which exceeded consensus expectations.
